Showing results (731-740 of 1,609) with videos related to

Sort By:
Pageof 161
JAMA Oncology|June 20, 2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled TrialMichael Cecchini, Ronald R Salem, Marie Robert, et al.
JAMA Oncology|March 21, 2024
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel TimeHassal Lee, Alexander Shakeel Bates, Shawneequa Callier, et al.
JAMA Oncology|September 14, 2023
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical TrialElizabeth M Swisher, Nadine Rayes, Deborah Bowen, et al.
JAMA Oncology|September 7, 2023
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled TrialMotoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, et al.
JAMA Oncology|August 17, 2023
Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients With Medicaid in Cancer Clinical TrialsJoseph M Unger, Hong Xiao, Riha Vaidya, et al.
JAMA Oncology|August 10, 2023
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialJens Huober, Patrik Weder, Karin Ribi, et al.
JAMA Oncology|January 4, 2024
Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 TrialZhaozhi Yang, Jin Meng, Xin Mei, et al.
JAMA Oncology|January 4, 2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the USDaniel M Kerekes, Alexander E Frey, Elizabeth H Prsic, et al.
JAMA Oncology|December 21, 2023
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical TrialTom Wei-Wu Chen, Ming-Shen Dai, Ling-Ming Tseng, et al.
JAMA Oncology|November 22, 2023
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical TrialPriyanka Sharma, Shane R Stecklein, Rachel Yoder, et al.
Pageof 161